Linafexor
- Generic Name
- Linafexor
- Drug Type
- Small Molecule
- Chemical Formula
- C28H25Cl2FN4O4
- CAS Number
- 2499656-04-9
- Unique Ingredient Identifier
- US5Q3KD5RD
A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06888115
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM
- Conditions
- ObesityDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Interventions
- Drug: CS0159 placebo
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT06492330
- Locations
- 🇨🇳
Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study of [14C]CS0159 in China Healthy Subjects
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT06098027
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 50
- Registration Number
- NCT05896137
- Locations
- 🇨🇳
The First Affiliated Hospital,Zhejiang University School of Medicine, HangZhou, Zhejiang, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05624294
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Cascade Pharmaceuticals, Inc
- Target Recruit Count
- 79
- Registration Number
- NCT05082779
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Inc., Daytona Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.